An Outcome Driven Approach

Our Acceleration Initiative projects are highly innovative, address a significant challenge in pediatric cancer drug development, and have a strong probability of clinical application — ready to reach patients within three to five years. To learn more about the grant application process, click here.


Gregory Friedman, MD
University of Alabama at Birmingham
Focus: Pediatric High-Grade Glioma 
Project title: Overcoming the Adverse Microenvironment of Pediatric High-Grade Gliomas

David Langenau, PhD
Massachusetts General Hospital 
Focus: Rhabdomyosarcoma
Project Title:Targeting p53 in childhood rhabdomyosarcoma

Andrei Thomas-Tikhonenko, PhD
Children’s Hospital of Philadelphia 
Focus: High-risk Pediatric Cancers – Neuroblastoma and Diffuse Midline Glioma 
Project title: Targeting splicing-derived neo-epitopes in high-risk pediatric cancers

Frequently Asked Questions

Pin It on Pinterest

Scroll to Top